Bayer scoops up women’s healthcare biotech KaNDy Therapeutics in potential $1bn+ deal

pharmafile | August 11, 2020 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Bayer, KaNDy Therapeutics, menopause, pharma 

Bayer is set to acquire UK-based biotech KaNDy Therapeutics, assimilating the firm’s women’s healthcare development portfolio in a newly announced deal potentially worth $875 million, or even over $1 billion.

Under the agreement, Bayer will pay an upfront payment of $425 million, with a further $450 million available to KaNDy on the achievement of various milestones until the drug is launched. After this, the agreement promises further “triple digit million” milestone payments to be made once sales goals are hit.

The focus of the deal is KaNDy’s neurokinin-1,3 receptor antagonist known as NT-814, which has recently shown promise in the treatment of moderate to severe vasomotor symptoms due to menopause, with a Phase 3 study planned in 2021. It has been projected that, if successful, the drug could rake in as much as €1 billion in global sales at its peak.

Dr. Mary Kerr, Co-Founder and CEO of KaNDy Therapeutics, said of the new partnership: “Bayer has been our preferred partner due to its leading position in the area of women’s healthcare. We believe that under the ownership of Bayer, this potential first in class medicine can be optimally developed to become an important non-hormonal treatment option for women suffering vasomotor symptoms due to menopause.”

The deal is expected to close by September this year.

Matt Fellows

Related Content


FDA approves new nonhormonal medication for menopause hot flashes

The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content